title: CNS involvement in mantle-cell lymphoma.
abstract: OBJECTIVE
  In non-Hodgkin's lymphomas, CNS involvement is highly dependent on the histology of the lymphoma. Mantle-cell lymphoma (MCL) is a lymphoma type with distinctive histologic, biologic, and clinical features in which CNS involvement has only been rarely described. The purpose of this report is to describe the incidence, clinical characteristics, and outcome of CNS infiltration in patients with MCL seen at a single institution.
  
  
  METHODS
  Twenty-two patients with MCL, who account for 6% of all patients with nodal lymphomas diagnosed and monitored at a university hospital from 1987 to 1994, were studied. Analysis of the incidence of CNS involvement by the disease was performed.
  
  
  RESULTS
  Five of 22 patients (22%; exact 95% confidence interval [CI], 7.8% to 45.4%) with MCL developed CNS involvement at a median of 18 months (range, 6 to 59) from diagnosis. All of these patients presented with poor MCL histologic subtypes and advanced disease. When the CNS infiltration became apparent, all of the patients displayed neurologic signs and had lymphoid cells consistent with the diagnosis of MCL in the CSF. In most of the cases, CNS infiltration was part of resistant disease or generalized relapse and had an ominous significance.
  
  
  CONCLUSIONS
  The incidence of CNS involvement in MCL might be higher than previously recognized. The frequency of CNS infiltration in MCL deserves to be investigated in other series and, if a high incidence is confirmed, the risk factors, mechanisms, and clinical implications of such a complication should be further studied.
authors.affiliation: Postgraduate School of Hematology "Farreras Valentí," Barcelona, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Montserrat
authors.forename: F
authors.initials: F
authors.lastname: Bosch
authors.forename: A
authors.initials: A
authors.lastname: López-Guillermo
authors.forename: F
authors.initials: F
authors.lastname: Graus
authors.forename: M J
authors.initials: MJ
authors.lastname: Terol
authors.forename: E
authors.initials: E
authors.lastname: Campo
authors.forename: C
authors.initials: C
authors.lastname: Rozman
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction